Chloe Orkin MBE, MB BCh, MSc

Dr. Chloe Orkin has been a Consultant Physician at Barts Health NHS Trust since 2003 and was appointed by Queen Mary University in 2019. She leads an internationally renowned therapeutic trials unit that has made major contributions to the development and licensing of around 20 novel therapies. She specialises in long-acting therapeutics and is the global lead author for the FLAIR study, which evaluated the first-ever long-acting injectable HIV therapy and was published in the NEJM. Chloe led the practice-changing blood-borne virus testing campaign Going Viral.

Her research focuses on inclusive study design and the ways of including and engaging women, pregnant women, racially minoritised people, and older adults in clinical trials.

During mpox, she established an international research collaboration (SHARE-net) that delivered four impactful clinical manuscripts, which have changed international guidelines. She was an advisor to WHO Europe on mpox.

As past Chair of the British HIV Association (2016-19) she challenged discriminatory legislation and is considered a global medical leader for the U=U campaign.

Chloe has led both nationally and locally within the field of Equity, Diversity, and Inclusion (EDI). She was the past President of the Medical Women’s Federation and the former Academic EDI lead for the Faculty of Medicine and Athena Swan Chair. She has been named in the top 100 LGBTQ+ influencers (2020; Diva magazine) and in the Disability Power Influencer Top 100 (2023; Shaw Trust). She speaks and is interviewed regularly on podcasts on leadership, sexism, homophobia, and ableism. She has published on inequities in research and in the workforce.